Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude

Intermittent Hypoxia Clinical Trial

Official title:

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03588676
• Other study ID #: UCSD170200
• Status: Completed
• Phase: N/A
• Start date: January 10, 2018
• Est. completion date: December 10, 2018

Study information

• Verified date: August 2019
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low oxygen at altitude causes pauses in breathing during sleep, called central sleep apnea. Central sleep apnea causes repeated awakenings and poor sleep. Low oxygen itself and the induced oxidative stress can damage mental function which is likely worsened by poor sleep. Reduced mental function due to low oxygen can pose a serious danger to mountain climbers. However there is also mounting evidence that even in populations of people that live at high altitudes and are considered adapted, low oxygen contributes to reductions in learning and memory. Therefore there is a serious need for treatments which may improve sleep, control of breathing and mental function during low oxygen.Therefore this study aims to determine how melatonin effects control of breathing, sleep and mental performance during exposure to low oxygen.

Description:

Research has shown that exposure to low oxygen at altitude causes neurocognitive impairment (impaired mental processing, memory, attention, learning, etc). This impairment in cognitive performance poses a serious risk to mountain climbers and while it has traditionally been thought that people who live at high altitude have adapted to it, evidence shows there is still considerable damage to the brain and impairments in cognitive function of people who live and work at high altitude.

As every cell in the body requires oxygen to survive and function, impairment in cognitive performance at altitude is thought mainly due to reduced oxygen availability to the central nervous system. However, low oxygen at altitude also causes unstable breathing during sleep which results in short periods where the brain stops sending the signal to breath, called central sleep apnea (CSA). During apneas (pauses in breathing) blood oxygen drops even lower and people typically wake up briefly and hyperventilate after apneas. Therefore at altitude people usually get less sleep, their sleep is broken with periods of wakefulness during the night and they experience repeated bouts of severe low blood oxygen levels. Sleep plays a critical role in how the brain repairs and also converts newly acquired information into long-term memory. Therefore broken and reduced sleep can impair cognitive performance, memory and learning. Repeated bouts of severe low oxygen also produces highly reactive molecules that cause damage to cells, called oxidative stress. Oxidative stress also prevents the brain from forming long-term memories and in severe cases (such as extremely high altitude and long duration exposure) can cause neurons in the brain to die. Therefore although sustained low oxygen at altitude likely impairs cognitive function, disturbed sleep and repeated bouts of severely low oxygen likely also contribute to causing brain damage and impaired cognitive performance.

Melatonin is a hormone produced in the pineal gland of the brain during the night which signals to the brain that it is time to sleep. Melatonin is also a very powerful antioxidant which naturally helps to prevent damage in the body from oxidative stress. A study previously reported that melatonin taken 90 mins before bed at 4,300 m (14,200 ft) reduced the time taken to fall asleep, it reduced the number of times people woke up during sleep and improved cognitive performance the following day. However how melatonin caused these effects was not determined. Therefore this study aims to determine how melatonin affects ventilatory control, sleep and neurocognitive performance during sustained hypoxia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: December 10, 2018
• Est. primary completion date: December 10, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy Males and Females

• Age:18-65 years

Exclusion Criteria:

• Sleep Disorders

• Pregnant Females

• Smokers (quit = 1 year ago acceptable)

• Cardiovascular, Pulmonary, Renal, Neurologic, Neuromuscular, or Hepatic Issues

• Diabetes

• Psychiatric disorder, other than mild depression

• Recent exposure to altitude (>8000ft) in the last month or having slept at an altitude >6000ft in the last month

Related Conditions & MeSH terms

• Hypoxia
• Intermittent Hypoxia

Intervention

Other:
• Melatonin
5mg Melatonin
• Placebo
5mg Placebo capsule

Locations

Country	Name	City	State
United States	University of California, San Diego	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Robert L. Owens

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Apnea Hypopnea Index	Measure of Sleep Apnea severity	6 weeks
Primary	Neurocognitive Scores	Reflex changes between conditions	6 weeks
Secondary	Loop Gain	Measurement of breathing characteristics during sleep using a flow meter attached to a CPAP mask that allows the measurement of expiratory flow	6 weeks
Secondary	Arousal Threshold	requirements for sleep arousal to occur	6 weeks
Secondary	Sleep Efficiency	Time in bed divided by total sleep time	6 weeks
Secondary	Total Antioxidant Status	Measurement taken from blood draw	6 weeks
Secondary	Hypoxic Ventilatory Response	Change in breathing response while breathing low oxygen	6 weeks
Secondary	Hypercapnic Ventilatory Response	Change in breathing response while breathing high carbon dioxide	6 weeks

External Links

•   Study Website